Combination treatment may affect IOP results.

Article

Using diclofenac sodium 0.1% and latanoprost 0.005% simultaneously could affect intraocular pressure (IOP) in glaucoma patients

Using diclofenac sodium 0.1% and latanoprost 0.005% simultaneously could affect intraocular pressure (IOP) in glaucoma patients, according to a study published in the Journal of Glaucoma.

Dr Rana Sorkhabi et al., Department of Ophthalmology, Nikookari Eye Center, Tabriz University of Medical Sciences, Iran, studied 22 patients with bilateral primary open angle glaucoma. Each patient was administered latanoprost for 4 weeks.

The patients were given topical diclofenac sodium in one eye and hydroxypropyl methyl cellulose was given in the other. This was completed 4 times a day for a fortnight. IOP was measured 2 weeks after treatment and 2 weeks after stopping other ophthalmic treatments.

The findings revealed additional administration of diclofenac sodium raised mean IOP from 15.73±1.75 to 17.32±2.23 mmHg. Two weeks after patients stopped using additional solutions, IOP was reduced. The control group did not show any significant difference in mean IOP. When co-administrating diclofenac sodium and latanoprost, the possibility of interference should be considered.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.